0000899243-19-023377.txt : 20190911 0000899243-19-023377.hdr.sgml : 20190911 20190911214557 ACCESSION NUMBER: 0000899243-19-023377 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190911 FILED AS OF DATE: 20190911 DATE AS OF CHANGE: 20190911 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CRUTCHFIELD BRADFORD CENTRAL INDEX KEY: 0001246406 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39035 FILM NUMBER: 191089425 MAIL ADDRESS: STREET 1: 6230 STONERIDGE MALL ROAD CITY: PLEASANTON STATE: CA ZIP: 94547 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: 10x Genomics, Inc. CENTRAL INDEX KEY: 0001770787 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 455614458 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6230 STONERIDGE MALL ROAD CITY: PLEASANTON STATE: CA ZIP: 94588 BUSINESS PHONE: (925) 401-7300 MAIL ADDRESS: STREET 1: 6230 STONERIDGE MALL ROAD CITY: PLEASANTON STATE: CA ZIP: 94588 FORMER COMPANY: FORMER CONFORMED NAME: 10X Genomics, Inc. DATE OF NAME CHANGE: 20190315 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2019-09-11 0 0001770787 10x Genomics, Inc. TXG 0001246406 CRUTCHFIELD BRADFORD C/O 10X GENOMICS, INC. 6230 STONERIDGE MALL ROAD PLEASANTON CA 94588 0 1 0 0 Chief Commercial Officer Stock Option (right to buy) 1.16 2027-02-03 Class B Common Stock 800000 D Stock Option (right to buy) 1.20 2027-10-18 Class B Common Stock 25000 D Stock Option (right to buy) 5.04 2028-11-02 Class B Common Stock 125000 D Stock Option (right to buy) 11.48 2029-05-10 Class B Common Stock 70000 D One-fourth of the shares subject to the option vested on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. This option may be exercised prior to vesting, subject to the Issuer's right to repurchase unvested shares. Each share of Class B Common Stock shall be reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock. One forty-eighth of the shares subject to the option vested on October 1, 2017 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. One forty-eighth of the shares subject to the option vested on October 1, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. One forty-eighth of the shares subject to the option vested on May 1, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Exhibit 24 - Power of Attorney /s/ Eric S. Whitaker, as Attorney-in-Fact 2019-09-11 EX-24 2 attachment1.htm EX-24 DOCUMENT

                                 POWER OF ATTORNEY

Know all by these presents that the undersigned, does hereby make, constitute
and appoint each of Serge Saxonov, Justin J. McAnear and Eric S. Whitaker, or
any one of them, as a true and lawful attorney-in-fact of the undersigned with
full powers of substitution and revocation, for and in the name, place and stead
of the undersigned (in the undersigned's individual capacity), to execute and
deliver such forms that the undersigned may be required to file with the U.S.
Securities and Exchange Commission as a result of the undersigned's ownership
of or transactions in securities of 10x Genomics, Inc. (i) pursuant to Section
16(a) of the Securities Exchange Act of 1934, as amended, including without
limitation, statements on Form 3, Form 4 and Form 5 (including any amendments
thereto) and (ii) in connection with any applications for EDGAR access codes,
including without limitation the Form ID. The Power of Attorney shall remain in
full force and effect until the undersigned is no longer required to file
Forms 3, 4 and 5 with regard to his or her ownership of or transactions in
securities of 10x Genomics, Inc., unless earlier revoked in writing. The
undersigned acknowledges that Serge Saxonov, Justin J. McAnear and Eric S.
Whitaker are not assuming any of the undersigned's responsibilities to
comply with Section 16 of the Securities Exchange Act of 1934, as amended.

            By: /s/ Bradford J. Crutchfield
                --------------------------------
            Name: Bradford J. Crutchfield




            Date: September 9, 2019